A case of severe thrombocytopenia in a patient with chronic hepatitis C caused by a single administration of pegylated interferon α 2a subsequent to 48 weeks of pegylated interferon α 2b plus ribavirin therapy

Intern Med. 2010;49(16):1741-4. doi: 10.2169/internalmedicine.49.3586. Epub 2010 Aug 13.

Abstract

A 54-year-old female with chronic hepatitis C developed severe thrombocytopenia after a single administration of Peg-IFN alpha 2a subsequent to 48 weeks of Peg-IFN alpha-2b plus ribavirin therapy. The platelet count decreased from 11.3 x 10(4) /mm(3) to 1.6 x 10(4) /mm(3). Blood test and bone marrow aspiration examination indicated that an immunological mechanism was considered for the etiology of platelet decrease. Fifty mg of prednisolone was administered and the platelet count gradually increased to the normal range. This case is very instructive since severe thrombocytopenia did not occur during 48 weeks of Peg-IFN alpha-2b plus ribavirin therapy, but occurred after a single subcutaneous administration of Peg-IFN alpha-2a during a subsequent course.

Publication types

  • Case Reports

MeSH terms

  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Female
  • Hepatitis C, Chronic / blood
  • Hepatitis C, Chronic / drug therapy*
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / administration & dosage*
  • Interferon-alpha / adverse effects*
  • Middle Aged
  • Polyethylene Glycols / administration & dosage*
  • Polyethylene Glycols / adverse effects*
  • Recombinant Proteins
  • Ribavirin / administration & dosage*
  • Severity of Illness Index*
  • Thrombocytopenia / blood
  • Thrombocytopenia / chemically induced*
  • Thrombocytopenia / diagnosis

Substances

  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Polyethylene Glycols
  • Ribavirin
  • peginterferon alfa-2b
  • peginterferon alfa-2a